Apellis Pharmaceuticals (Apellis Pharmaceuticals) Price-to-Tangible-Book : 29.17 (As of May. 05, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Apellis Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-05-05), Apellis Pharmaceuticals's share price is $47.46. Apellis Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $1.63. Hence, Apellis Pharmaceuticals's Price to Tangible Book Ratio of today is 29.17.

The historical rank and industry rank for Apellis Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

APLS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.61 Med: 23.21 Max: 57.23
Current: 29.12

During the past 11 years, Apellis Pharmaceuticals's highest Price to Tangible Book Ratio was 57.23. The lowest was 4.61. And the median was 23.21.

APLS's Price-to-Tangible-Book is ranked worse than
97.22% of 1222 companies
in the Biotechnology industry
Industry Median: 2.715 vs APLS: 29.12

A closely related ratio is called PB Ratio. As of today, Apellis Pharmaceuticals's share price is $47.46. Apellis Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $1.63. Hence, Apellis Pharmaceuticals's P/B Ratio of today is 29.17.

Apellis Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Apellis Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals Price-to-Tangible-Book Chart

Apellis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

Get a 7-Day Free Trial

57.23

21.29

23.21

33.71

36.79

Apellis Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															33.71	18.60	31.01	19.39	36.79

Competitive Comparison of Apellis Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Apellis Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apellis Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apellis Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Apellis Pharmaceuticals's Price-to-Tangible-Book falls into.

Apellis Pharmaceuticals Price-to-Tangible-Book Calculation

Apellis Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	47.46	/	1.627
	=	29.17

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Apellis Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Apellis Pharmaceuticals (Apellis Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (NAS:APLS) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

1JK:Germany

Address

100 Fifth Avenue, Waltham, MA, USA, 02451

Website

https://www.apellis.com

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

Executives

Karen Lewis	officer: Chief People Officer	APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Mark Jeffrey Delong	officer: Senior Vice President	100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
James George Chopas	officer: See Remarks	950 WINTER STREET, WALTHAM MA 02451
Adam J. Townsend	officer: See Remarks	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
David O. Watson	officer: General Counsel	6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Pascal Deschatelets	officer: Chief Operating Officer	6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Jeffrey Eisele	officer: See Remarks	APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Nur Nicholson	officer: Chief Technical Officer	APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Timothy Eugene Sullivan	officer: Chief Financial Officer	800 BOYLSTON ST., SUITE 3310, PRUDENTIAL TOWER C/O AJU IB INVESTMENT, BOSTON MA 02199
Cedric Francois	director, 10 percent owner, officer: Chief Executive Officer	6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Caroline Baumal	officer: Chief Medical Officer	C/O APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
A. Sinclair Dunlop	director	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Lukas Scheibler	officer: See Remarks	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Alec Machiels	director	505 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10022
Federico Grossi	officer: See Remarks	C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014